December of 2018 saw the FDA release their “Framework For Evaluating the Potential Use of Real-World Evidence (RWE)” to support the approval of a new indication for a drug already approved under section 505(c) of the FD&C Act. This document was developed to outline guidance and support of real world data collection efforts for post-approval […]
Read MoreGeorge Clinical is proud to have been involved in developing the recently announced recommendations by the Clinical Trial Transformation Initiative (CTTI): The Recommendations for Engaging Patients and Sites in Mobile Clinical Trials. The recommendations, to which George Clinical contributed as a member on the expert committee, aim to help research organizations, sponsors, and other stakeholders […]
Read MoreSYDNEY, May 29, 2019 – George Clinical, a global scientifically-backed clinical research organization (CRO), has again expanded its extensive Asia-Pacific footprint through the opening of a new office in the Philippines. The office is based in the capital city, Manila and compliments the organization’s growing list of global locations. The opening of this office […]
Read MoreSYDNEY, May 15, 2019 – George Clinical, a global scientifically-backed clinical research organization (CRO), has significantly expanded its capabilities in Taiwan having been granted a license to import drugs into the country for clinical trials on behalf of sponsors. The development will be particularly helpful for small to mid-sized clinical trial clients who do not […]
Read MoreSydney, Australia, April 24, 2019 – EPS International Holdings Co., Ltd. (HQ: Tokyo, Japan; Representative Director and President: Hisashi Tanaka; “EPSI” hereafter) and George Clinical Pty Ltd (HQ: Sydney, Australia; Executive Chairman: Glenn Kerkhof; “George Clinical” hereafter) announced today that they have reached an agreement on a strategic partnership that will enhance their combined service offerings […]
Read MoreNoxopharm, a clinical-stage Australian drug development company currently working with George Clinical, is seeking to establish Veyonda®, an innovative dosage formulation of the experimental anti-cancer drug idronoxil, as “an essential adjunct to all forms of radiotherapy in the treatment of prostate cancer, both late-stage and early-stage prostate cancer,” according to an announcement last week. Through […]
Read More
OneOncology, a national partnership of community oncologists, recently announced that Lee Schwartzberg, MD, FACP, a member of the George Clinical scientific leadership committee, has been named Chief Medical Officer (CMO). According to OneOncology, the CMO position “provides a dynamic link between OneOncology and its physician partners, demonstrating the shared, foundational commitment to a physician-driven, data-driven, technology-powered, […]
Read More
ISN World Congress of Nephrology will be live streaming “Late Breaking Clinical Trials” from WCN 2019. The purpose of the webcast is to give the worldwide nephrology community in-depth understanding of three major nephrology studies, including the CREDENCE study for which George Clinical plays a critical role. The session will be streamed live from […]
Read MoreGeorge Clinical, a global scientifically backed clinical research organization, (CRO) has expanded its footprint in Asia with the addition of a new presence in Singapore. The new office and entity in Singapore, which was established in July, were requisites for George Clinical to act as a local clinical trial sponsor for the firm’s international client […]
Read More
OVERLAND PARK, KS, March 6, 2019 George Clinical, a leading Asia-Pacific based clinical research organization (CRO) with global capabilities, today announced that Dr. Maria Ali has been promoted to Chief Medical Officer to be based out of Raleigh, North Carolina. This move further solidifies the strategic growth of George Clinical throughout North America and recognizes […]
Read More
